Varo, Rosauro, Crowley, Valerie M, Mucasse, Humberto, Sitoe, Antonio, Bramugy, Justina, Serghides, Lena, Weckman, Andrea M 
ORCID: 0000-0002-2200-4008, Erice, Clara ORCID: 0000-0001-9681-6861, Bila, Rubao, Vitorino, Pio et al (show 10 more authors)
(2024)
Adjunctive rosiglitazone treatment for severe pediatric malaria: A randomized placebo-controlled trial in Mozambican children.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 139.
pp. 34-40.
Abstract
<h4>Objectives</h4>We tested the hypothesis that adjunctive rosiglitazone treatment would reduce levels of circulating angiopoietin-2 (Angpt-2) and improve outcomes of Mozambican children with severe malaria.<h4>Methods</h4>A randomized, double-blind, placebo-controlled trial of rosiglitazone vs placebo as adjunctive treatment to artesunate in children with severe malaria was conducted. A 0.045 mg/kg/dose of rosiglitazone or matching placebo were administered, in addition to standard of malaria care, twice a day for 4 days. The primary endpoint was the rate of decline of Angpt-2 over 96 hours. Secondary outcomes included the longitudinal dynamics of angiopoietin-1 (Angpt-1) and the Angpt-2/Angpt-1 ratio over 96 hours, parasite clearance kinetics, clinical outcomes, and safety metrics.<h4>Results</h4>Overall, 180 children were enrolled; 91 were assigned to rosiglitazone and 89 to placebo. Children who received rosiglitazone had a steeper rate of decline of Angpt-2 over the first 96 hours of hospitalization compared to children who received placebo; however, the trend was not significant (P = 0.28). A similar non-significant trend was observed for Angpt-1 (P = 0.65) and the Angpt-2/Angpt-1 ratio (P = 0.34). All other secondary and safety outcomes were similar between groups (P >0.05).<h4>Conclusion</h4>Adjunctive rosiglitazone at this dosage was safe and well tolerated but did not significantly affect the longitudinal kinetics of circulating Angpt-2.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Humans, Malaria, Malaria, Falciparum, Antimalarials, Double-Blind Method, Child, Mozambique, Rosiglitazone, Artesunate |
| Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 19 Feb 2024 08:39 |
| Last Modified: | 19 Feb 2024 08:39 |
| DOI: | 10.1016/j.ijid.2023.11.031 |
| Open Access URL: | https://doi.org/10.1016/j.ijid.2023.11.031 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3178759 |
Dimensions
Dimensions
